MURANO
Venetoclax + Rituximab in Relapsed/Refractory CLL
Paciente / Población Intervención / Exposición Comparación Desenlace
In 389 patients with relapsed or refractory chronic lymphocytic leukaemia, fixed-duration venetoclax + rituximab for two years improved progression-free survival compared with bendamustine + rituximab.
N
389
Diseño
Open-label RCT
Desenlace
Progression-free survival
Relevancia
2
ResultadoPFS HR 0.17; 2-yr PFS 84.9% vs 36.3%. 4-yr OS 85.3% vs 66.8% (HR 0.41).
Seymour JF, et al. N Engl J Med. 2018;378(12):1107-1120; Kater AP, et al. J Clin Oncol. 2020;38(34):4042-4054. 10.1056/NEJMoa1713976
Discusión y crítica
Established fixed-duration, MRD-driven, chemotherapy-free therapy in R/R CLL — a paradigm now extended to first-line treatment (CLL14).